Smith Group Asset Management’s Heron Therapeutics HRTX Stock Holding History

Smith Group Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-120	Closed	-$1K	–	320
2021 Q4	$1K	Hold	120	–	–	﹤0.01%	365
2021 Q3	$1K	Hold	120	–	–	﹤0.01%	368
2021 Q2	$2K	Hold	120	–	–	﹤0.01%	358
2021 Q1	$2K	Sell	120 -3,600	-97%	-$64.2K	﹤0.01%	324
2020 Q4	$79K	Hold	3,720	–	–	﹤0.01%	209
2020 Q3	$55K	Buy	3,720 +910	+32%	+$14.2K	﹤0.01%	213
2020 Q2	$41K	Sell	2,810 -30	-1%	-$493	﹤0.01%	212
2020 Q1	$33K	Hold	2,840	–	–	﹤0.01%	263
2019 Q4	$67K	Hold	2,840	–	–	﹤0.01%	261
2019 Q3	$53K	Buy	2,840 +530	+23%	+$9.76K	﹤0.01%	275
2019 Q2	$43K	Hold	2,310	–	–	﹤0.01%	282
2019 Q1	$56K	Sell	2,310 -6,600	-74%	-$173K	﹤0.01%	294
2018 Q4	$231K	Hold	8,910	–	–	0.01%	229
2018 Q3	$282K	Buy	+8,910	New	+$332K	0.01%	226

Other funds holding HRTX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Smith Group Asset Management's HRTX Position: Q1 2022 in Review

Smith Group Asset Management sold out of Heron Therapeutics (HRTX) in Q1 2022, closing a stake of 120 shares — an estimated $1K sold.

Smith Group Asset Management first reported a position in HRTX in Q3 2018 and held it in 14 quarters. The position peaked at $282K in Q3 2018. 186 funds tracked by Wall St. Rank hold HRTX as of Q1 2022.

Smith Group Asset Management reported no remaining Heron Therapeutics position as of Q1 2022 after selling out during the quarter.
Smith Group Asset Management sold 120 Heron Therapeutics shares in Q1 2022, an estimated $1K.
Smith Group Asset Management first reported a position in Heron Therapeutics in Q3 2018 and held it in 14 quarters.
Smith Group Asset Management's Heron Therapeutics position peaked at $282K in Q3 2018.
186 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2022.

Based on Smith Group Asset Management's 13F filing for Q1 2022, filed 5 May 2022.